For the quarter ending 2026-03-31, CPMD made $627,462 in revenue. -$116,159 in net income. Net profit margin of -18.51%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 627,462 | 138,630 | 656,606 | 231,608 |
| Cost of goods sold | 1,036,915 | 659,721 | 1,096,606 | 852,818 |
| Gross loss | -409,453 | -521,091 | -440,000 | -621,210 |
| Payroll and consulting fees | - | 0* | 0 | 0 |
| Depreciation | - | - | 0 | 0 |
| General and administrative | 35,814 | 240,534 | 145,444 | 75,952 |
| Professional fees | 105,856 | 129,144 | 115,990 | 88,219 |
| Royalty expense | 131,220 | 12,669* | 234,212 | 55,599 |
| Imputed interest expense | - | -71,096* | 187,242 | - |
| Total operating expenses | 272,890 | 382,347 | 495,646 | 219,770 |
| Loss on the extinguishment of debt | - | 0* | 0 | 0 |
| Loss from operations | -682,343 | -903,438 | -935,646 | -840,980 |
| Change in the fair value of derivative conversion feature | 801,038 | -930,753* | 7,296 | 46,438 |
| Change in the fair value of obligation to issue shares | 317,527 | -4,481,867.25* | 168,355 | 46,033 |
| Foreign exchange loss (gain) | -31,084 | -98,275.5* | 24,243 | 85,442 |
| Loss on impairment of investment | - | 1,129,531.75* | - | - |
| Interest expense | 475,617 | 179,423 | 506,331 | 657,515 |
| Gain on write-off of accounts payable and accrued liabilities | - | 102,607.5* | - | - |
| Imputed interest expense | 311,542 | - | - | - |
| Other expense | 0 | 0 | 0 | 0 |
| Total other income (expenses) | 300,322 | -6,646,147 | -542,165 | -572,478 |
| Net loss | -382,021 | -7,549,585 | -1,477,811 | -1,413,458 |
| Foreign currency translation adjustment | 265,862 | -230,201 | 278,300 | -653,505 |
| Net comprehensive loss | -116,159 | -7,779,786 | -1,199,511 | -2,066,963 |
| Diluted EPS | 0 | -0.012 | 0 | 0 |
| Basic Average Shares | - | - | 662,501,405 | 662,501,405 |
| Diluted Average Shares | 669,790,294 | 662,501,405 | - | - |
CANNAPHARMARX, INC. (CPMD)
CANNAPHARMARX, INC. (CPMD)